

Are We Ready to View Artificial Intelligence Not as a Threat but as Supplementary and/or Supplemental Intelligence?

In 2025, the United Nations Educational, Scientific and Cultural Organization (UNESCO) dedicated January 24th, the International Day of Education, to celebrate artificial intelligence (AI).¹⁻³ In medicine, AI is still under evaluation until the possibilities of a negative impact on patient care can be confidently excluded; fears persist that biases and errors in clinical data could result in suboptimal algorithms with increased healthcare disparities, breaches in privacy of patient data, and decreased transparency in decision-making.⁴⁻¹⁶ In the bigger picture, there are concerns that AI could lead to a partial/panoramic attrition in original thinking, creativity, ingenuity, and innovation.¹⁶⁻¹⁹

This issue needs serious thought. The use of electronic tools to augment functional efficiency is not entirely new—all of us have been using online search engines to polish/expand our ideas now for many years. Most of us have searched for synonyms, antonyms, sentence constructs, historical context, online articles, and blogs with opinions.²⁰ And does this ethical dilemma of “artificially” enhancing efficiency/productivity²¹ not remind of the times when automobiles began to replace horse-carts? When typewriters replaced human calligraphers? Calculators for elementary mathematics? Basic computers for calculators? Using artistic fonts with these computers to replace calligraphers? Computing with databases has altered the life of chartered accountants. In medicine, electronic medical records have changed our way of storing details of a patient’s medical history and hospital events.²² This list could go on.

There are definitely some concerns. But AI has the potential to revolutionize many aspects of life—there can be a quantal impact on efficiency that would make it difficult to ignore it completely.²³ And all things considered, its advent and rapid progression in many areas of medicine so far is making it look unstoppable (Fig. 1).^{24,25} Hence, we need to think—should we continue to consider it as “artificial”, which has a negative connotation,²⁶ or accept it and call it “supplementary”, or additional intelligence that augments human functionality.²⁷ In certain areas, it might even deserve further recognition to be called “supplemental”, to acknowledge that many of these software programs can independently add to the efficiency of cognitive tasks.²⁸ We will definitely need to get together to evaluate AI for its merits and deficiencies for different tasks—no one solution will fit all.²⁹ In medicine, there are enormous possibilities in complex/high-volume data analysis, repetitive tasks, decision-making, personalized tailored therapy, and simulating human-like interaction.³⁰ It might also be useful in quality control and improvement; service automation, generation of creative content for personalized family education, monitoring of environmental factors by bringing in multisource expertise, and in development of accessible technology for infants with disabilities.³¹⁻³⁸ In research, the possibilities are even stronger, be it as one of the tools for literature search, for preliminary study design prior to expert review, additional training of personnel, and in integration of data—from *in vitro* studies of gene regulation to protein interaction to pathway analysis in neural networks or other methods, to evaluation/enhancement or even as an alternative to animal models, to development of chemical modulators/“drugs”, and to human safety/efficacy studies.³⁹⁻⁴⁷ There could be more.




Fig. 1: Artificial intelligence is transforming medicine. When we look at the areas of impact in research and clinical medicine, the question is not about the likely areas of growth, but is more to identify the areas that would not benefit from correct application. Maybe we would be better off in getting involved to set priorities and prevent misuse. The cart is already in motion.

© The Author(s). 2025 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Moving from this line of discussion, we once again remind our readers and ourselves that the Global Newborn Society (GNS) aims to be a worldwide social movement for improving neonatal care. Recent commitments of financial support from the Mozib Center for Neonatal Care (Bangladesh) and the Carlo GNS Center for Saving Lives at Birth (USA) have added momentum. Since the last issue, 10 newly formed or existing organizations have joined the efforts; these include the Global Newborn Society Iran Chapter; National Federation of Neonatologists of Mexico; College of Neonatologists of the State of Jalisco, Mexico; The Skylar Project; American Society for Black Lives; Friends Aid Africa, Bukedea, Uganda; Society for Bacteriophage Research and Therapy; the GNS Center for Computational Scientific Methodology; the GNS International Association of Neonatal POCUS; and the SABREE Enrichment Academy: Empowering Ability. We are excited about all the possibilities emerging in underserved geographic areas and populations, our understanding of the biological modifiers of bacterial pathogens, and novel monitoring systems of critically-ill/extremely premature infants. We have unfortunately lost the company of one organization, the GNS Cardiology Association of Iraq, because of their changed needs. Currently, our group is comprised of the GNS and 47 other organizations. We consult each other and share scientific data, viewpoints, and our experiences relevant for care of newborn infants in various parts of the world.

In each issue of this journal, our editorial team highlights the achievements of one of our partnering members. Here, we recollect the efforts of the neonatology team at the Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, to develop a human milk bank (HMB) compliant with Islamic religious practices (Fig. 2).^{48,49} There are more than 500 large HMBs in the world but only a few are functioning in Muslim countries.⁵⁰ Islamic laws do not allow infants to receive human milk from multiple unidentified donors.⁵¹ To comply with these guidelines, milk from each donor has to be processed and stored separately, and can be provided to an infant only after counseling both the donor and recipient families about Islamic laws of prohibition of future marriages between milk siblings.⁵² All relevant records need to be maintained for future reference. After extensive review of the proposals by the country's health services and Islamic foundations and community debates,⁵³ this HMB was developed with allocation of appropriate hospital space, investment in necessary equipment, and extensive training of personnel. The facility was finally inaugurated in December 2019.⁵⁴

Our team would like to express our sincere gratitude to Professor Dr Robert D Christensen,^{55,56} who is retiring from active academics after many decades of service. His contributions to neonatal hematology and large-cohort clinical research are known the world over. All of us hope and believe that he will resume his scholarly activities after a brief period of much-deserved rest. He has promised that he will remain available for guidance and solutions based on his experience. We need him.

This journal aims to cover fetal/neonatal problems that begin during pregnancy, at the time of birth, or during the first 1,000 days after birth.⁵⁷ As in our previous issues, we present 8 articles here (Fig. 3). Hoyos et al.⁵⁸ have presented a new set of guidelines for adequate nutrition to promote growth for premature neonates. Although optimal postnatal growth should ideally replicate intrauterine rates, most premature infants lose weight for the first few days before resuming slow weight gains that are usually below intrauterine rates.⁵⁹ This extrauterine growth restriction (EUGR) can be seen at the time of discharge with lower weight Z-score medians than those



Figs 2A to F. Development of a human milk bank in Bangladesh. (A and B) The Special Care Neonatal Unit and Neonatal Intensive Care Unit at the Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, are respected for having saved countless newborn lives in the region; (C) In Islam, there are many important restrictions on sharing milk from one lactating mother between multiple infants. Considering the life-saving importance of human milk feeds, the Institute of Child Health at the BSMMU established a core medical group to discuss the possibilities for developing a socially accepted, religiously compliant human milk bank; (D and E) These potential solutions were reviewed by the National Health Services and Islamic Foundations, first together and then in smaller groups for in-depth discussions; (F) After much effort by medical and social leaders, a human milk bank was inaugurated in December 2019.




Fig. 3: Areas of focus in the newborn, Volume 4, Issue 1. We have expanded the traditional agent-host-environment trinodal disease model to a hexagonal system. The three additional foci represent extrinsic factors that can affect health—those originating in therapy, nutrition, and systems management are shown. This issue covers 5 nodes, with articles focused on agents, host factors, therapy/monitoring systems, nutrition, and systems management.

at birth.^{60–62} The authors hypothesized that improved nutrition could reduce the incidence of EUGR in convalescing premature infants. They reviewed the clinical information of 480 infants born at ≤ 32 weeks' gestational age in EpicLatino units in the past 8 years. Even though the sample size was not large enough to establish causality, the authors noted that nutrition was not effective as the sole intervention. The risk of EUGR was higher in infants with higher severity of illness.

Bacterial infections are a leading cause of morbidity and mortality in premature and critically ill neonates.⁶³ In another quality-improvement (QI) study, Shah et al.⁶⁴ reviewed the spectrum of bacterial infections in their neonatal intensive care unit over a 10-year period. They identified 151 culture-positive bacterial sepsis events in 125 infants. The spectrum of bacterial isolates largely remained similar during the study period. Early-onset sepsis (EOS) was caused most frequently by *Escherichia coli* (*E. coli*) and group B *Streptococcus*, whereas the leading causes of late-onset sepsis (LOS) were coagulase-negative *Staphylococcus* (CoNS) and methicillin-sensitive *Staphylococcus aureus*. There was a trend for increasing *Klebsiella* isolates since 2015. Overall, there was no significant shift in organisms causing neonatal infections in this hospital during the last decade. This study is an important template; these bacterial isolates need to be monitored in all centers, all over the world.

Gomez Pomar et al.⁶⁵ compared the clinical profile of premature infants who developed hyponatremia, defined as plasma sodium (Na) < 135 mEq/L, during their clinical course. Existing studies have suggested that infants who receive donor human milk may be at higher risk of having low serum Na levels.^{66,67} In this cohort, 60 infants were noted to have developed hyponatremia at some point, including 32 who received supplemental Na and 28 who did not. These were compared with 29 controls. Contrary to assumptions, most infants with hyponatremia received more mothers' own, not donor, milk. They might have had a higher severity of illness. Sodium chloride supplementation did not always correct serum Na levels or improve the growth parameters at discharge. Further studies are needed.

Boyd et al.⁶⁸ have studied the technical feasibility of a novel noninvasive prototype instrument for measuring ingested milk volumes in 24 neonates. A monitor recorded feeding sounds via a microphone placed on the infant's neck, and a secondary microphone captured background noise for cancellation. This modality could help in serial monitoring of milk intake in breast-fed infants without disrupting the natural nursing process because test-weighing during the feeding session is not necessary. Power spectral density analysis⁶⁹ was performed to differentiate swallow and non-swallow events, and a linear regression model⁷⁰ was then used to estimate feed volumes based on 20 recordings. More studies are needed in larger cohorts.

Al-Ethawi et al.⁷¹ reviewed existing information on factors that might affect outcomes of premature infants with congenital heart defects following corrective surgical interventions. Many pathophysiological changes related to surgery-related tissue disruption and cardiopulmonary bypass include Na/water overload, systemic inflammatory response syndrome (SIRS), and ischemia/reperfusion in the heart and other major organs are seen during this period.⁷² Focused intensive care is needed with close monitoring of cardiac function, tissue oxygenation, hemostasis, pain control, and sedation.⁷³ There are also some center-specific needs; all care-providers need to reach a consensus on evidence-based protocols for initiation, maintenance, and weaning from assisted ventilation, which can facilitate earlier extubation and prevent ventilation-related complications.^{74,75} Finally, a clearly defined discharge protocol can enhance safety.⁷⁶

Singh and Maheshwari⁷⁷ have reviewed the presence and mechanisms of innate immune memory of prior stimuli in macrophages in infants. This memory is rooted in epigenetic regulation of lineage- and tissue-specific transcription that may enhance/suppress immune responses to repeated exposures to a stimulus.^{78,79} In this article, they have specifically focused on lineage-determining changes such as those in the erythroblast transformation-specific gene purine-rich sequence binding protein 1 (PU.1) and histone methylation, and have also outlined the role of several other newly discovered regulators.^{80–82} These changes promote macrophage differentiation into several phenotypes essential for host defense or tissue homeostasis in response to environmental stimuli.⁸³ Maladaptive changes in macrophages can disrupt the normal sequence of immune/inflammatory responses and predispose to disease states.⁸⁴

Raghavendra et al.⁸⁵ have described a 36-week-gestation infant of a diabetic mother with an unusually severe and persistent neonatal small colon syndrome (NSCS).⁸⁶ She manifested signs of intestinal obstruction at about 6 hours after birth and a contrast enema showed a small caliber distal small intestine and colon. There was no clinical improvement over the next 2 weeks and so an exploratory laparotomy was performed after much discussion. Intra-operatively, the surgeons noted viscous meconium with pellets in

the involved bowel and later histopathological examination showed normal bowel histoarchitecture with an appropriate morphology/number of ganglion cells.⁸⁷ A double barrel enterostomy was created and the distal gastrointestinal tract was regularly flushed. She then showed good improvement and was discharged home. The authors want to remind that NSCS may not always show prompt, spontaneous resolution and should be considered in the differential diagnosis of a newborn infant with unusually prolonged signs of intestinal obstruction.⁸⁸ Some of these infants may require surgical management with ostomy formation.⁸⁹

Finally, Ben Ayad et al.⁹⁰ call for caution about the risk of secondary hypothyroidism in infants with large omphaloceles who are managed conservatively with topical iodine on polymeric carriers. There are two well-accepted strategies for management of giant omphaloceles (GOs): (a) surgical closure after initial stabilization;⁹¹ or (b) a more conservative “paint and wait” strategy without graft closure.⁹² In this second protocol, the sac is maintained with topical medications such as silver sulfadiazine or combinations of polyvinylpyrrolidone (povidone), iodine, and, sometimes, with added topical antibiotics. This repeated exposure to iodine is usually tolerated well⁹³ but there is a need for cautious monitoring as some infants have been noted to develop thyroid dysfunction.⁹⁴ The authors present one such case; the goal is to sensitize the medical care-providers to these adverse effects.

References

1. UNESCO. 2025 International Day of Education New York, USA: United Nations; 2025 [Available from: <https://www.un.org/en/observances/education-day>].
2. UNESCO. UNESCO: Building Peace through Education, Science, Culture, Communication and Information. Paris, France: United Nations Educational, Scientific and Cultural Organization; 2025 [Available from: <https://www.unesco.org/en>].
3. IBM. What is artificial intelligence (AI)? New York: IBM (International Business Machines Corporation); 2025 [Available from: <https://www.ibm.com/think/topics/artificial-intelligence>].
4. Shiferaw KB, Roloff M, Balaur I, Welter D, Waltemath D, Zeleke AA. Guidelines and standard frameworks for artificial intelligence in medicine: a systematic review. *JAMIA Open*. 2025;8(1):ooae155. PMID: 39759773. doi: 10.1093/jamiaopen/ooae155.
5. Gaur K, Jagtap MM. Role of artificial intelligence and machine learning in prediction, diagnosis, and prognosis of cancer. *Cureus*. 2022;14(11):e31008. PMID: 36475188. doi: 10.7759/cureus.31008.
6. Choudhury A, Asan O. Role of artificial intelligence in patient safety outcomes: Systematic literature review. *JMIR Med Inform*. 2020;8(7):e18599. PMID: 32706688. doi: 10.2196/18599.
7. Mittermaier M, Raza MM, Kvedar JC. Bias in AI-based models for medical applications: challenges and mitigation strategies. *NPJ Digit Med*. 2023;6(1):113. PMID: 37311802. doi: 10.1038/s41746-023-00858-z.
8. Evans H, Snead D. Understanding the errors made by artificial intelligence algorithms in histopathology in terms of patient impact. *NPJ Digit Med*. 2024;7(1):89. PMID: 38600151. doi: 10.1038/s41746-024-01093-w.
9. Li G, Li C, Wang C, Wang Z. Suboptimal capability of individual machine learning algorithms in modeling small-scale imbalanced clinical data of local hospital. *PLoS One*. 2024;19(2):e0298328. PMID: 38394317. doi: 10.1371/journal.pone.0298328.
10. Nazer LH, Zatarah R, Waldrip S, Ke JXC, Moukheiber M, Khanna AK, et al. Bias in artificial intelligence algorithms and recommendations for mitigation. *PLoS Digit Health*. 2023;2(6):e0000278. PMID: 37347721. doi: 10.1371/journal.pdig.0000278.
11. Cross JL, Choma MA, Onofrey JA. Bias in medical AI: Implications for clinical decision-making. *PLoS Digit Health*. 2024;3(11):e0000651. PMID: 39509461. doi: 10.1371/journal.pdig.0000651.
12. Yu L, Li Y. Artificial intelligence decision-making transparency and employees' trust: The parallel multiple mediating effect of effectiveness and discomfort. *Behav Sci (Basel)*. 2022;12(5). PMID: 35621424. doi: 10.3390/bs12050127.
13. Haider SA, Borna S, Gomez-Cabello CA, Pressman SM, Haider CR, Forte AJ. The algorithmic divide: A systematic review on AI-driven racial disparities in healthcare. *J Racial Ethn Health Disparities*. 2024. PMID: 39695057. doi: 10.1007/s40615-024-02237-0.
14. Murdoch B. Privacy and artificial intelligence: challenges for protecting health information in a new era. *BMC Med Ethics*. 2021;22(1):122. PMID: 34525993. doi: 10.1186/s12910-021-00687-3.
15. Li J. Security implications of AI chatbots in health care. *J Med Internet Res*. 2023;25:e47551. PMID: 38015597. doi: 10.2196/47551.
16. Price WN, 2nd, Cohen IG. Privacy in the age of medical big data. *Nat Med*. 2019;25(1):37–43. PMID: 30617331. doi: 10.1038/s41591-018-0272-7.
17. Ahmad SF, Han H, Alam MM, Rehmat MK, Irshad M, Arrano-Munoz M, et al. Impact of artificial intelligence on human loss in decision making, laziness and safety in education. *Humanit Soc Sci Commun*. 2023;10(1):311. PMID: 37325188. doi: 10.1057/s41599-023-01787-8.
18. Doshi AR, Hauser OP. Generative AI enhances individual creativity but reduces the collective diversity of novel content. *Sci Adv*. 2024;10(28):eadn5290. PMID: 38996021. doi: 10.1126/sciadv.adn5290.
19. Koivisto M, Grassini S. Best humans still outperform artificial intelligence in a creative divergent thinking task. *Sci Rep*. 2023;13(1):13601. PMID: 37709769. doi: 10.1038/s41598-023-40858-3.
20. Wang L, Wang J, Wang M, Li Y, Liang Y, Xu D. Using Internet search engines to obtain medical information: a comparative study. *J Med Internet Res*. 2012;14(3):e74. PMID: 22672889. doi: 10.2196/jmir.1943.
21. WEF. Top 9 ethical issues in artificial intelligence. Cologny, Switzerland: World Economic Forum; 2016 [Available from: <https://www.weforum.org/stories/2016/10/top-10-ethical-issues-in-artificial-intelligence/>].
22. Evans RS. Electronic health records: Then, now, and in the future. *Yearb Med Inform*. 2016;Suppl 1(Suppl 1):S48–61. PMID: 27199197. doi: 10.15265/IYS-2016-s006.
23. Lee C, Britto S, Diwan K. Evaluating the impact of artificial intelligence (ai) on clinical documentation efficiency and accuracy across clinical settings: A scoping review. *Cureus*. 2024;16(11):e73994. PMID: 39703286. doi: 10.7759/cureus.73994.
24. Benet D, Pellicer-Valero OJ. Artificial intelligence: the unstoppable revolution in ophthalmology. *Surv Ophthalmol*. 2022;67(1):252–270. PMID: 33741420. doi: 10.1016/j.survophthal.2021.03.003.
25. Jheng YC, Kao CL, Yarmishyn AA, Chou YB, Hsu CC, Lin TC, et al. The era of artificial intelligence-based individualized telemedicine is coming. *J Chin Med Assoc*. 2020;83(11):981–983. PMID: 32568967. doi: 10.1097/JCMA.0000000000000374.



26. Jo-hannssen C, Märki M, Zurich ETH. Psychological understanding of the term 'artificial'. Cologny, Switzerland: World Economic Forum; 2021 [Available from: https://phys.org/news/2021-06-psychological-term-artificial.html#google_vignette].
27. Price A, Schroter S, Clarke M, McAneney H. Role of supplementary material in biomedical journal articles: surveys of authors, reviewers and readers. *BMJ Open*. 2018;8(9):e021753. PMID: 30249629. doi: 10.1136/bmjopen-2018-021753.
28. Batsis JA, Apolzan JW, Bagley PJ, Blunt HB, Divan V, Gill S, et al. A systematic review of dietary supplements and alternative therapies for weight loss. *Obesity (Silver Spring)*. 2021;29(7):1102–1113. PMID: 34159755. doi: 10.1002/oby.23110.
29. Chustecki M. Benefits and risks of AI in health care: Narrative review. *Interact J Med Res*. 2024;13:e53616. PMID: 39556817. doi: 10.2196/53616.
30. Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. *Future Healthc J*. 2021;8(2):e188–e194. PMID: 34286183. doi: 10.7861/fhj.2021-0095.
31. Mahmood U, Shukla-Dave A, Chan HP, Drukker K, Samala RK, Chen Q, et al. Artificial intelligence in medicine: mitigating risks and maximizing benefits via quality assurance, quality control, and acceptance testing. *BJR Artif Intell*. 2024;1(1):ubae003. PMID: 38476957. doi: 10.1093/bjrai/ubae003.
32. Kazzazi F. The automation of doctors and machines: A classification for AI in medicine (ADAM framework). *Future Healthc J*. 2021;8(2):e257–e262. PMID: 34286194. doi: 10.7861/fhj.2020-0189.
33. Lin H, Chen Q. Artificial intelligence (AI)-integrated educational applications and college students' creativity and academic emotions: students and teachers' perceptions and attitudes. *BMC Psychol*. 2024;12(1):487. PMID: 39285268. doi: 10.1186/s40359-024-01979-0.
34. Almansour M, Alfahid FM. Generative artificial intelligence and the personalization of health professional education: A narrative review. *Medicine (Baltimore)*. 2024;103(31):e38955. PMID: 39093806. doi: 10.1097/MD.00000000000038955.
35. Shaban-Nejad A, Michalowski M, Bianco S. Creative and generative artificial intelligence for personalized medicine and healthcare: Hype, reality, or hyperreality? *Exp Biol Med (Maywood)*. 2023;248(24):2497–2499. PMID: 38311873. doi: 10.1177/15353702241226801.
36. Xu H, Yang X, Hu Y, Wang D, Liang Z, Mu H, et al. Trusted artificial intelligence for environmental assessments: An explainable high-precision model with multi-source big data. *Environ Sci Ecotechnol*. 2024;22:100479. PMID: 39286480. doi: 10.1016/j.ese.2024.100479.
37. Iannone A, Giansanti D. Breaking barriers—The intersection of AI and Assistive technology in autism care: A narrative review. *J Pers Med*. 2023;14(1). PMID: 38248742. doi: 10.3390/jpm14010041.
38. Zdravkova K, Krasniqi V, Dalipi F, Ferati M. Cutting-edge communication and learning assistive technologies for disabled children: An artificial intelligence perspective. *Front Artif Intell*. 2022;5:970430. PMID: 36388402. doi: 10.3389/frai.2022.970430.
39. Jin Q, Leaman R, Lu Z. PubMed and beyond: biomedical literature search in the age of artificial intelligence. *EBioMedicine*. 2024;100:104988. PMID: 38306900. doi: 10.1016/j.ebiom.2024.104988.
40. Schoeb D, Suarez-Ibarrola R, Hein S, Dressler FF, Adams F, Schlager D, et al. Use of artificial intelligence for medical literature search: Randomized controlled trial using the Hackathon Format. *Interact J Med Res*. 2020;9(1):e16606. PMID: 32224481. doi: 10.2196/16606.
41. Zhang B, Zhang L, Chen Q, Jin Z, Liu S, Zhang S. Harnessing artificial intelligence to improve clinical trial design. *Commun Med (Lond)*. 2023;3(1):191. PMID: 38129570. doi: 10.1038/s43856-023-00425-3.
42. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26(1):80–93. PMID: 33099022. doi: 10.1016/j.drudis.2020.10.010.
43. Ferrara M, Bertozzi G, Di Fazio N, Aquila I, Di Fazio A, Maiese A, et al. Risk management and patient safety in the artificial intelligence era: A systematic review. *Healthcare (Basel)*. 2024;12(5). PMID: 38470660. doi: 10.3390/healthcare12050549.
44. Chen H, Cohen E, Wilson D, Alfred M. A Machine learning approach with human-AI collaboration for automated classification of patient safety event reports: Algorithm development and validation study. *JMIR Hum Factors*. 2024;11:e53378. PMID: 38271086. doi: 10.2196/53378.
45. Pacholec C, Flatland B, Xie H, Zimmerman K. Harnessing artificial intelligence for enhanced veterinary diagnostics: A look to quality assurance, Part I Model development. *Vet Clin Pathol*. 2024. PMID: 39638756. doi: 10.1111/vcp.13401.
46. Ghosh A, Choudhary G, Medhi B. The pivotal role of artificial intelligence in enhancing experimental animal model research: A machine learning perspective. *Indian J Pharmacol*. 2024;56(1):1–3. PMID: 38454581. doi: 10.4103/ijp.ijp_81_24.
47. Rudroff T. Artificial intelligence as a replacement for animal experiments in neurology: Potential, progress, and challenges. *Neurol Int*. 2024;16(4):805–820. PMID: 39195562. doi: 10.3390/neurolint16040060.
48. Rahman MM, Khatun S, Kabir N, Khanam W, Maheshwari A, Shahidullah M. Establishment of the first religiously-compliant human milk bank in Bangladesh. *Newborn (Clarksville)*. 2022;1(4). doi: 10.5005/jp-journals-11002-0047.
49. BSMMU. Neonatology, Bangabandhu Sheikh Mujib Medical University Dhaka, Bangladesh: BSMMU; 2025 [Available from: <https://bsmmu.ac.bd/page/130>].
50. Alnakshabandi K, Fiester A. Creating religiously compliant milk banks in the Muslim world: a commentary. *Paediatr Int Child Health*. 2016;36(1):4–6. PMID: 26750779. doi: 10.1080/20469047.2015.1110336.
51. El-Khuffash A, Unger S. The concept of milk kinship in Islam: issues raised when offering preterm infants of Muslim families donor human milk. *J Hum Lact*. 2012;28(2):125–127. PMID: 22311893. doi: 10.1177/0890334411434803.
52. Subudhi S, Sriraman N. Islamic beliefs about milk kinship and donor human milk in the United States. *Pediatrics*. 2021;147(2). PMID: 33483451. doi: 10.1542/peds.2020-0441.
53. Thompson S. Milk banks for premature babies: Religious debates in Bangladesh. *World Faiths Development Dialogue: Berkley Center for Religion, Peace, and World Affairs*; 2020 [Available from: <https://berkeleycenter.georgetown.edu/posts/milk-banks-for-premature-babies-religious-debates-in-bangladesh>].
54. Reza PR. Bangladesh's first Human Milk Bank faces challenges before inauguration The Hague, Netherlands: Global Voices; 2019 [Available from: <https://globalvoices.org/2019/12/30/bangladeshs-first-human-milk-bank-faces-challenges-before-inauguration/>].
55. Scilit. Robert D. Christensen. Basel, Switzerland: Scilit.com; 2025 [Available from: <https://www.scilit.com/scholars/16719820>].
56. Utah Uo. Robert D. Christensen Salt Lake City, Utah, USA: University of Utah; 2025 [Available from: <https://medicine.utah.edu/faculty/robert-d-christensen>].

57. Global-Newborn-Society. Newborn Clarksville, MD, USA: Global Newborn Society; 2021 [updated 2024. Available from: <https://www.globalnewbornsociety.org/our-scientific-journal-newborn>.
58. Hoyos AB, Salas A, Osiovič H, Fajardo CA, Baez M, Monterrosa L, et al. Using Weight Z-score differences between birth and discharge (Δ Z-score) to compare and monitor nutritional outcomes in neonatal units in Latin America using the EpicLatino database: Variables that are associated with poor growth. *Newborn (Clarksville)*. 2025;4(1):1–5. doi: 10.5005/jp-journals-11002-0117.
59. Bertino E, Coscia A, Mombro M, Boni L, Rossetti G, Fabris C, et al. Postnatal weight increase and growth velocity of very low birthweight infants. *Arch Dis Child Fetal Neonatal Ed*. 2006;91(5):F349–56. PMID: 16638781. doi: 10.1136/adc.2005.090993.
60. Bagga N, Panigrahi N, Germain A, Namazova I, Rahman MM, Saugstad OD, et al. Extrauterine Growth Restriction: Need for an Accurate Definition. *Newborn (Clarksville)*. 2023;2(3):198–202. PMID: 37974930. doi: 10.5005/jp-journals-11002-0072.
61. Edwards EM, Greenberg LT, Horbar JD, Gagliardi L, Adams M, Berger A, et al. Discharge age and weight for very preterm infants in six countries: 2012–2020. *Neonatology*. 2023;120(2):208–216. PMID: 36649689. doi: 10.1159/000528013.
62. Simon L, Hanf M, Frondas-Chauty A, Darmaun D, Rouger V, Gascoïn G, et al. Neonatal growth velocity of preterm infants: The weight Z-score change versus Patel exponential model. *PLoS One*. 2019;14(6):e0218746. PMID: 31251763. doi: 10.1371/journal.pone.0218746.
63. De Rose DU, Ronchetti MP, Martini L, Rechichi J, Iannetta M, Dotta A, et al. Diagnosis and management of neonatal bacterial sepsis: Current challenges and future perspectives. *Trop Med Infect Dis*. 2024;9(9). PMID: 39330888. doi: 10.3390/tropicalmed9090199.
64. Shah P, Malik SK, Motiani J, Lozy T, Bhavsar S. Evaluation of neonatal infections in the NICU over a 10-year period. *Newborn (Clarksville)*. 2025;4(1):6–12. doi: 10.5005/jp-journals-11002-0115.
65. Gomez Pomar E, McMasters H, Adams J, Robertson M. Donor vs maternal breast milk and factors associated with hyponatremia in preterm infants. *Newborn (Clarksville)*. 2025;4(1):13–18. doi: 10.5005/jp-journals-11002-0119.
66. Araya BR, Ziegler AA, Grobe CC, Grobe JL, Segar JL. Sodium and growth in preterm infants: A review. *Newborn (Clarksville)*. 2023;2(2):142–147. PMID: 37614871. doi: 10.5005/jp-journals-11002-0060.
67. Perrin MT, Friend LL, Sisk PM. Fortified donor human milk frequently does not meet sodium recommendations for the preterm infant. *J Pediatr*. 2022;244:219–223e1. PMID: 35093320. doi: 10.1016/j.jpeds.2022.01.029.
68. Boyd RS, Grooby ES, Bhuiyan H, Anaya DV, Rad HN, Malhotra A, et al. Infaeed monitor pilot study: Measuring ingested milk volumes in neonates. *Newborn (Clarksville)*. 2025;4(1):19–24. doi: 10.5005/jp-journals-11002-0121.
69. Youngworth RN, Gallagher BB, Stamper BL. An overview of power spectral density (PSD) calculations. *Optics and Photonics 2005; San Diego, California, USA*. 2005;5869:206–216. DOI: 10.1117/12.618478.
70. Castro HM, Ferreira JC. Linear and logistic regression models: when to use and how to interpret them? *J Bras Pneumol*. 2023;48(6):e20220439. PMID: 36651441. doi: 10.36416/1806-3756/e20220439.
71. Al-Ethawi S, Sadick NIA, Hameed SA, Salih AH, Ben Ayad A, Alsharari NM, et al. Perioperative care after surgical correction of congenital heart defects in premature infants. *Newborn (Clarksville)*. 2025;4(1):25–35. doi: 10.5005/jp-journals-11002-0122.
72. Ferreira LO, Vasconcelos VW, Lima JS, Vieira Neto JR, da Costa GE, Esteves JC, et al. Biochemical Changes in cardiopulmonary bypass in cardiac surgery: New Insights. *J Pers Med*. 2023;13(10). PMID: 37888117. doi: 10.3390/jpm13101506.
73. Cheung PY, Hajihosseini M, Dinu IA, Switzer H, Joffe AR, Bond GY, et al. Outcomes of preterm infants with congenital heart defects after early surgery: Defining risk factors at different time points during hospitalization. *Front Pediatr*. 2020;8:616659. PMID: 33585367. doi: 10.3389/fped.2020.616659.
74. Tham SQ, Lim EHL. Early extubation after pediatric cardiac surgery. *Anesth Pain Med (Seoul)*. 2024;19(Suppl 1):S61–S72. PMID: 39069653. doi: 10.17085/apm.23154.
75. Harris KC, Holowachuk S, Pitfield S, Sanatani S, Froese N, Potts JE, et al. Should early extubation be the goal for children after congenital cardiac surgery? *J Thorac Cardiovasc Surg*. 2014;148(6):2642–2647. PMID: 25156467. doi: 10.1016/j.jtcvs.2014.06.093.
76. Dodds KM, Merle C. Discharging neonates with congenital heart disease after cardiac surgery: a practical approach. *Clin Perinatol*. 2005;32(4):1031–1042, xi. PMID: 16325676. doi: 10.1016/j.clp.2005.09.009.
77. Singh S, Maheshwari A. Epigenetic regulation of macrophage polarization. *Newborn (Clarksville)*. 2025;4(1):36–48. doi: 10.5005/jp-journals-11002-0118.
78. Maheshwari A. Innate Immune Memory in Macrophages. *Newborn (Clarksville)*. 2023;2(1):60–79. PMID: 37206580. doi: 10.5005/jp-journals-11002-0058.
79. Nair J, Maheshwari A. Epigenetics in Necrotizing Enterocolitis. *Curr Pediatr Rev*. 2021;17(3):172–184. PMID: 33882811. doi: 10.2174/1573396317666210421110608.
80. Minderjahn J, Schmidt A, Fuchs A, Schill R, Raithel J, Babina M, et al. Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1. *Nat Commun*. 2020;11(1):402. PMID: 31964861. doi: 10.1038/s41467-019-13960-2.
81. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. *Nat Rev Genet*. 2012;13(5):343–357. PMID: 22473383. doi: 10.1038/nrg3173.
82. Chen S, Yang J, Wei Y, Wei X. Epigenetic regulation of macrophages: from homeostasis maintenance to host defense. *Cell Mol Immunol*. 2020;17(1):36–49. PMID: 31664225. doi: 10.1038/s41423-019-0315-0.
83. Mezu-Ndubuisi OJ, Maheshwari A. Role of macrophages in fetal development and perinatal disorders. *Pediatr Res*. 2021;90(3):513–523. PMID: 33070164. doi: 10.1038/s41390-020-01209-4.
84. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. *Nat Immunol*. 2016;17(1):34–40. PMID: 26681460. doi: 10.1038/ni.3324.
85. Raghavendra PR, Nair S, Goyal M, Nathan MV, Haribalakrishna A, Sathe PA. Neonatal small colon syndrome in infants of diabetic mothers: Is it always a transient condition? *Newborn (Clarksville)*. 2025;4(1):49–52. doi: 10.5005/jp-journals-11002-0116.
86. Stewart DR, Nixon GW, Johnson DG, Condon VR. Neonatal small left colon syndrome. *Ann Surg*. 1977;186(6):741–745. PMID: 603277. doi: 10.1097/0000658-197712000-00014.
87. Lotfollahzadeh S, Taherian M, Anand S. Hirschsprung disease. Treasure Island (FL): StatPearls Publishing; 2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562142/>.



88. Davis WS, Campbell JB. Neonatal small left colon syndrome. Occurrence in asymptomatic infants of diabetic mothers. *Am J Dis Child.* 1975;129(9): 1024–1027. PMID: 1190176. doi: 10.1001/archpedi.1975.02120460014004.
89. Philippart AI, Reed JO, Georgeson KE. Neonatal small left colon syndrome: intramural not intraluminal obstruction. *J Pediatr Surg.* 1975;10(5): 733–740. PMID: 1185461. doi: 10.1016/0022-3468(75)90378-4.
90. Ben Ayad AA, Abdullatif M. Neonatal hypothyroidism following prolonged exposure to povidone-iodine in a preterm infant with giant omphalocele: A case report and call for awareness. *Newborn (Clarksville).* 2025;4(1):53–57. doi: 10.5005/jp-journals-11002-0120.
91. Ghattaura H, Ross A, Aldeiri B, Mutanen A, Saxena A. Managing giant omphalocele: A systematic review of surgical techniques and outcomes. *Acta Paediatr.* 2024;113(11):2459–2465. PMID: 38992931. doi: 10.1111/apa.17346.
92. Wagner JP, Cusick RA. Paint and wait management of giant omphaloceles. *Semin Pediatr Surg.* 2019;28(2):95–100. PMID: 31072465. doi: 10.1053/j.sempedsurg.2019.04.005.
93. Whitehouse JS, Gourlay DM, Masonbrink AR, Aiken JJ, Calkins CM, Sato TT, et al. Conservative management of giant omphalocele with topical povidone-iodine and its effect on thyroid function. *J Pediatr Surg.* 2010;45(6):1192–1197. PMID: 20620319. doi: 10.1016/j.jpedsurg.2010.02.091.
94. Cosman BC, Schullinger JN, Bell JJ, Regan JA. Hypothyroidism caused by topical povidone-iodine in a newborn with omphalocele. *J Pediatr Surg.* 1988;23(4):356–358. PMID: 3385590. doi: 10.1016/s0022-3468(88)80207-0.

Akhil Maheshwari, MD
Kei Lui, MD
Mario Motta, MD